In vivo tumor targeting specificity of 131I-YZHER2: V2 against HER2-positive tumors was further confirmed by observing a significant increase in tumor uptake during biological distribution experiments conducted 1 h post-injection. The gene discussed is ERBB2; the disease is neoplasm.